
## Nazia Thakur

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4526376/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Differential susceptibility of SARSâ€CoVâ€2 in animals: Evidence of ACE2 host receptor distribution in companion animals, livestock and wildlife by immunohistochemical characterisation. Transboundary and Emerging Diseases, 2022, 69, 2275-2286.	1.3	33
2	Mutations that adapt SARS-CoV-2 to mink or ferret do not increase fitness in the human airway. Cell Reports, 2022, 38, 110344.	2.9	46
3	Porcine Respiratory Coronavirus as a Model for Acute Respiratory Coronavirus Disease. Frontiers in Immunology, 2022, 13, 867707.	2.2	11
4	The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies. EBioMedicine, 2022, 77, 103902.	2.7	23
5	SARS-CoV-2 variants of concern alpha, beta, gamma and delta have extended ACE2 receptor host ranges. Journal of General Virology, 2022, 103, .	1.3	19
6	Pseudotyped Bat Coronavirus RaTG13 is efficiently neutralised by convalescent sera from SARS-CoV-2 infected patients. Communications Biology, 2022, 5, 409.	2.0	5
7	Neutralizing antibody activity against 21 SARS-CoV-2 variants in older adults vaccinated with BNT162b2. Nature Microbiology, 2022, 7, 1180-1188.	5.9	39
8	Micro-fusion inhibition tests: quantifying antibody neutralization of virus-mediated cell–cell fusion. Journal of General Virology, 2021, 102, .	1.3	21
9	A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses. Nature Communications, 2021, 12, 542.	5.8	200
10	A booster dose enhances immunogenicity of the COVID-19 vaccine candidate ChAdOx1 nCoV-19 in aged mice. Med, 2021, 2, 243-262.e8.	2.2	62
11	Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7. Cell Reports, 2021, 35, 109292.	2.9	375
12	ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models. Communications Biology, 2021, 4, 915.	2.0	15
13	Combinatorial F-G Immunogens as Nipah and Respiratory Syncytial Virus Vaccine Candidates. Viruses, 2021, 13, 1942.	1.5	10
14	The circadian clock component BMAL1 regulates SARS-CoV-2 entry and replication in lung epithelial cells. IScience, 2021, 24, 103144.	1.9	34
15	Production of Recombinant Replication-defective Lentiviruses Bearing the SARS-CoV or SARS-CoV-2 Attachment Spike Glycoprotein and Their Application in Receptor Tropism and Neutralisation Assays. Bio-protocol, 2021, 11, e4249.	0.2	10
16	Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19. Npj Vaccines, 2020, 5, 69.	2.9	121
17	Bovine Herpesvirus-4-Vectored Delivery of Nipah Virus Glycoproteins Enhances T Cell Immunogenicity in Pigs. Vaccines, 2020, 8, 115.	2.1	27
18	The SARS-CoV-2 Spike protein has a broad tropism for mammalian ACE2 proteins. PLoS Biology, 2020, 18, e3001016.	2.6	169

Nazia Thakur

#	Article	IF	CITATIONS
19	The SARS-CoV-2 Spike protein has a broad tropism for mammalian ACE2 proteins. , 2020, 18, e3001016.		0
20	The SARS-CoV-2 Spike protein has a broad tropism for mammalian ACE2 proteins. , 2020, 18, e3001016.		0
21	The SARS-CoV-2 Spike protein has a broad tropism for mammalian ACE2 proteins. , 2020, 18, e3001016.		0
22	The SARS-CoV-2 Spike protein has a broad tropism for mammalian ACE2 proteins. , 2020, 18, e3001016.		0
23	The SARS-CoV-2 Spike protein has a broad tropism for mammalian ACE2 proteins. , 2020, 18, e3001016.		0
24	The SARS-CoV-2 Spike protein has a broad tropism for mammalian ACE2 proteins. , 2020, 18, e3001016.		0
25	BST2/Tetherin Overexpression Modulates Morbillivirus Glycoprotein Production to Inhibit Cell–Cell Fusion. Viruses, 2019, 11, 692.	1.5	8
26	Advances in diagnostics, vaccines and therapeutics for Nipah virus. Microbes and Infection, 2019, 21, 278-286.	1.0	21